2 August 2024 · Ustekinumab biosimilars (Pyzchiva, Uzpruvo, Wezenla) are licensed. Learn about the indications, available formulations, supporting evidence and differences.
5 March 2024 · One licensed tocilizumab biosimilar is available: Tyenne. Learn about the licensed indications, supporting evidence and key differences.
29 June 2022 · Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
6 March 2024 · Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
4 June 2021 · The stability of several aseptically compounded ready to administer presentations of monoclonal antibody products and other biopharmaceuticals is presented.
16 July 2024 · Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
5 March 2024 · Introducing biosimilar tocilizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
29 June 2022 · Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team